OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Dermatology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040	242
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis	234
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis	229
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis	227
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis	187
Comparison of Biologics and Oral Treatments for Plaque Psoriasis	163
Psoriasis Prevalence in Adults in the United States	156
Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening	128
Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis	119
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis	117
Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic	113
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine	104
Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis	101
Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms	98
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis	87
Prevalence of Hidradenitis Suppurativa	84
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa	79
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic	77
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne	77
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis	76
Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	74
Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	68
Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology	68
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome	67
Systemic Immunomodulatory Treatments for Atopic Dermatitis	66

Association Between Medication Use and Bullous Pemphigoid	63
Evaluation of Sex-Specific Incidence of Melanoma	62
Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic	61
Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines	61
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders	57
Enanthem in Patients With COVID-19 and Skin Rash	57
UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color	57
Secukinumab Therapy for Netherton Syndrome	56
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy	56
Association of Wildfire Air Pollution and Health Care Use for Atopic Dermatitis and Itch	55
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab	55
Dermatologist Perceptions of Teledermatology Implementation and Future Use After COVID-19	54
Prognostic Gene Expression Profiling in Cutaneous Melanoma	54
Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic	53
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride	52
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis	49
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children	49
Association Between Atopic Eczema and Cancer in England and Denmark	48
A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria	46
Insurance Acceptance, Appointment Wait Time, and Dermatologist Access Across Practice Types in the US	46
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases	45